Latest Exclusive Distribution Agreements News

Memphasys is intensifying its direct sales efforts for the Felix™ sperm-selection device across key Middle East IVF clinics, positioning for rapid market activation upon CE Mark approval expected early 2026.

OMG Group has inked a five-year exclusive distribution agreement with SANDAI, a premium Japanese matcha producer, positioning itself to capture significant growth in Australia’s expanding matcha market.

Memphasys has sharpened its commercial focus on the Felix™ System, securing a major distribution expansion in the MENA region and cutting operational costs by 40%, setting the stage for a global market push.

Osteopore Limited reported a 7% year-on-year revenue increase in Q3 CY25, secured Swiss market approval for its implants, and saw a threefold sales surge through its Zimmer Biomet partnership.

Lumos Diagnostics reported steady quarterly revenue with a 300% surge in product sales, driven by its flagship FebriDx® test. The company inked a landmark US$317 million exclusive U.S. distribution agreement and awaits FDA feedback on its CLIA waiver application.

Memphasys Limited is intensifying its commercial push for Felix, an innovative automated sperm separation system for IVF, backed by a landmark Middle East partnership and a fresh capital raise to scale manufacturing and sales.

Memphasys has upgraded its contract with ITL to A$390,000 and expanded its territory to include Turkey, marking its first contracted revenues in the EU ahead of expected CE Mark approval.

Memphasys has inked a five-year exclusive distribution agreement with Middle East leader ITL, unlocking a $325,000 initial order for its Felix™ fertility system upon CE Mark approval. This deal opens access to 15 countries and over 350 IVF clinics, setting the stage for rapid regional adoption.

Mayne Pharma Group Limited reported a robust FY25 with a 5% revenue increase to A$408.1 million and a 105% surge in underlying EBITDA, driven by strong growth in Women’s Health and strategic acquisitions in Dermatology.

Memphasys Limited reported a net loss of AUD 4.94 million for FY25 while accelerating commercial efforts for its Felix System and advancing its RoXsta diagnostics platform.

DXN Limited reported a 49% surge in revenue to $16 million for FY25, driven by strong modular data centre contracts and a new Data Centre as a Service division, despite a slight increase in net loss to $2.31 million.

Sprintex Limited reported a 26% revenue increase for FY25 but also a 37% rise in net loss, as it accelerates global expansion through key distribution deals and manufacturing upgrades.